This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, C. Articles by Lumsden, A. B. Search for Related Content PubMed PubMed Citation Articles by Chen, C. Articles by Lumsden, A. B. Pubmed/NCBI databases Substance via MeSH Hazardous Substances DB TEFLON

(Circulation. 1996;94:1989-1995.)
© 1996 American Heart Association, Inc.

Articles

Recombinant Mitotoxin Basic Fibroblast Growth Factor–Saporin Reduces Venous Anastomotic Intimal Hyperplasia in the Arteriovenous Graft

Changyi Chen, MD; Samer G. Mattar, MB, ChB; John D. Hughes, MD; Glenn F. Pierce, MD, PhD; Jennifer E. Cook, MS; David N. Ku, MD, PhD; Stephen R. Hanson, PhD; Alan B. Lumsden, MB, ChB

the Departments of Surgery (C.C., S.G.M., J.D.H., D.N.K., A.B.L.) and Medicine (S.R.H.), Emory University School of Medicine, Atlanta, Ga, and Department of Preclinical Development, Prizm Pharmaceuticals, San Diego, Calif (G.F.P., J.E.C.).

Background The plant cytotoxin saporin (SAP) is a potent ribosome-inactivating protein. When conjugated to basic fibroblast growth factor (FGF2), it selectively kills proliferating cells that have upregulated FGF receptors. In this study, we evaluated the effect of the recombinant chimeric mitotoxin rFGF2-SAP on venous anastomotic intimal hyperplasia, a major cause of failure of arteriovenous (AV) grafts.

Methods and Results Recently designed expanded polytetrafluoroethylene–based local infusion devices were implanted bilaterally as femoral AV conduits in six dogs. The venous anastomoses were the sites of continuous delivery of rFGF2-SAP (2.7 µg·kg^-1·d^-1) to one side and vehicle (4.6 µL·kg^-1·d^-1) as control to the contralateral side for 14 days. All animals survived, and all grafts were patent. Liver enzyme levels and histological analyses of liver, kidneys, and brain were normal, indicating the absence of systemic toxicity. Morphometric measurements and measurements of cell proliferation by bromodeoxyuridine index analysis were performed at both arterial and venous anastomoses. There were no significant differences between the treated grafts and the control grafts in intimal hyperplasia and intimal cell proliferation at the arterial anastomoses. In contrast, rFGF2-SAP reduced intimal thickness by 32%, intimal area by 40%, and cell proliferation index by 33% at the treated venous anastomoses compared with the control venous anastomoses (P<.05).

Conclusions These data demonstrate that local infusion of rFGF2-SAP significantly reduces venous anastomotic intimal hyperplasia and cell proliferation without systemic toxicity. This study suggests a new strategy for reducing intimal hyperplasia by the selective killing of proliferating smooth muscle cells with a potent chimeric mitotoxin through a novel local infusion device.

Key Words: growth substances • saporin • hyperplasia • grafting

This article has been cited by other articles:

				J. Waltenberger Modulation of Growth Factor Action : Implications for the Treatment of Cardiovascular Diseases Circulation, December 2, 1997; 96(11): 4083 - 4094. [Abstract] [Full Text]

				A. Farb, S. J. Lee, D. H. Min, Z. Parandoosh, J. Cook, J. McDonald, G. F. Pierce, and R. Virmani Vascular Smooth Muscle Cell Cytotoxicity and Sustained Inhibition of Neointimal Formation by Fibroblast Growth Factor 2–Saporin Fusion Protein Circ. Res., April 19, 1997; 80(4): 542 - 550. [Abstract] [Full Text]